205 related articles for article (PubMed ID: 31324092)
1. Undergraduate Medical Teaching: Time to integrate?
Ravikirti ; Sharma S
J Assoc Physicians India; 2018 Aug; 66(8):85-86. PubMed ID: 31324092
[TBL] [Abstract][Full Text] [Related]
2. Current Status of Delamanid in the Management of MDR Tuberculosis.
Karekar SR; Marathe PA
J Assoc Physicians India; 2018 Jul; 66(7):72-75. PubMed ID: 31325268
[TBL] [Abstract][Full Text] [Related]
3. Delamanid: first global approval.
Ryan NJ; Lo JH
Drugs; 2014 Jun; 74(9):1041-5. PubMed ID: 24923253
[TBL] [Abstract][Full Text] [Related]
4. Delamanid for multidrug-resistant pulmonary tuberculosis.
Gler MT; Skripconoka V; Sanchez-Garavito E; Xiao H; Cabrera-Rivero JL; Vargas-Vasquez DE; Gao M; Awad M; Park SK; Shim TS; Suh GY; Danilovits M; Ogata H; Kurve A; Chang J; Suzuki K; Tupasi T; Koh WJ; Seaworth B; Geiter LJ; Wells CD
N Engl J Med; 2012 Jun; 366(23):2151-60. PubMed ID: 22670901
[TBL] [Abstract][Full Text] [Related]
5. Delamanid when other anti-tuberculosis-treatment regimens failed due to resistance or tolerability.
Kwon YS; Jeong BH; Koh WJ
Expert Opin Pharmacother; 2015 Feb; 16(2):253-61. PubMed ID: 25327169
[TBL] [Abstract][Full Text] [Related]
6. Delamanid for the treatment of pulmonary multidrug-resistant tuberculosis.
Thakare R; Soni I; Dasgupta A; Chopra S
Drugs Today (Barc); 2015 Feb; 51(2):117-23. PubMed ID: 25756067
[TBL] [Abstract][Full Text] [Related]
7. Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB).
Liu Y; Matsumoto M; Ishida H; Ohguro K; Yoshitake M; Gupta R; Geiter L; Hafkin J
Tuberculosis (Edinb); 2018 Jul; 111():20-30. PubMed ID: 30029909
[TBL] [Abstract][Full Text] [Related]
8. Delamanid: a review of its use in patients with multidrug-resistant tuberculosis.
Blair HA; Scott LJ
Drugs; 2015 Jan; 75(1):91-100. PubMed ID: 25404020
[TBL] [Abstract][Full Text] [Related]
9. Delamanid (OPC-67683) for treatment of multi-drug-resistant tuberculosis.
Sotgiu G; Pontali E; Centis R; D'Ambrosio L; Migliori GB
Expert Rev Anti Infect Ther; 2015 Mar; 13(3):305-15. PubMed ID: 25645397
[TBL] [Abstract][Full Text] [Related]
10. Profile of delamanid for the treatment of multidrug-resistant tuberculosis.
Szumowski JD; Lynch JB
Drug Des Devel Ther; 2015; 9():677-82. PubMed ID: 25678771
[TBL] [Abstract][Full Text] [Related]
11. Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study.
Ferlazzo G; Mohr E; Laxmeshwar C; Hewison C; Hughes J; Jonckheere S; Khachatryan N; De Avezedo V; Egazaryan L; Shroufi A; Kalon S; Cox H; Furin J; Isaakidis P
Lancet Infect Dis; 2018 May; 18(5):536-544. PubMed ID: 29452942
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.
Wirth D; Dass R; Hettle R
BMC Health Serv Res; 2017 Mar; 17(1):182. PubMed ID: 28270207
[TBL] [Abstract][Full Text] [Related]
13. Discovery and preclinical evaluations of JBD0131, a novel nitrodihydro-imidazooxazole anti-tuberculosis agent.
Luo W; Huang Z; Xu D; Yang M; Zhu Y; Shen L; Chen S; Tao X; Bin W; Hu Y; Franzblau SG; Jiang N; Wei Y; Wei X; Ding CZ
Bioorg Med Chem Lett; 2022 Sep; 72():128871. PubMed ID: 35777718
[TBL] [Abstract][Full Text] [Related]
14. Bedaquiline or delamanid for rifampin-resistant tuberculosis?
Lessem E; Cox V; Furin J
Lancet Respir Med; 2017 Oct; 5(10):772-774. PubMed ID: 28887015
[No Abstract] [Full Text] [Related]
15. Bedaquiline and delamanid in tuberculosis.
Esposito S; Bianchini S; Blasi F
Expert Opin Pharmacother; 2015; 16(15):2319-30. PubMed ID: 26293803
[TBL] [Abstract][Full Text] [Related]
16. Six-Month Response to Delamanid Treatment in MDR TB Patients.
Hewison C; Ferlazzo G; Avaliani Z; Hayrapetyan A; Jonckheere S; Khaidarkhanova Z; Mohr E; Sinha A; Skrahina A; Vambe D; Vasilyeva I; Lachenal N; Varaine F
Emerg Infect Dis; 2017 Oct; 23(10):1746-8. PubMed ID: 28767036
[TBL] [Abstract][Full Text] [Related]
17. Delamanid in the treatment of multidrug-resistant tuberculosis.
Gupta R; Wells CD; Hittel N; Hafkin J; Geiter LJ
Int J Tuberc Lung Dis; 2016 Dec; 20(12):33-37. PubMed ID: 28240570
[TBL] [Abstract][Full Text] [Related]
18. The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens.
Khan U; Huerga H; Khan AJ; Mitnick CD; Hewison C; Varaine F; Bastard M; Rich M; Franke MF; Atwood S; Khan PY; Seung KJ
BMC Infect Dis; 2019 Aug; 19(1):733. PubMed ID: 31429722
[TBL] [Abstract][Full Text] [Related]
19. Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis.
Bloemberg GV; Keller PM; Stucki D; Trauner A; Borrell S; Latshang T; Coscolla M; Rothe T; Hömke R; Ritter C; Feldmann J; Schulthess B; Gagneux S; Böttger EC
N Engl J Med; 2015 Nov; 373(20):1986-8. PubMed ID: 26559594
[TBL] [Abstract][Full Text] [Related]
20. Management of drug resistantTB in patients with HIV co-infection.
Pontali E; Sotgiu G; Centis R; D'Ambrosio L; Spanevello A; Migliori GB
Expert Opin Pharmacother; 2015; 16(18):2737-50. PubMed ID: 26478945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]